The FDA last month approved a new five-day 750 mg once-daffy regimen of Ortho-McNeil's Levaquin (levofloxacin) to treat acute bacterial sinusitis.
The newly approved regimen is as effective as a 10-day course of Levaquin 500 mg. Levaquin generated $1.3 billion in sales in 2004.
According to the National Ambulatory Medical Care Survey, sinusitis is the fifth most common condition for which an antibiotic is prescribed. Eachyear in the United States there are an estimated 20 million cases of acute bacterial sinusitis.
COPYRIGHT 2005 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2005 Gale Group